Amgen price target raised by Jefferies to $410 after positive Sjögren's data

Jefferies raised Amgen's price target by $43 to $410 from $367 after dazodalibep posted positive Phase 3 results in systemic Sjögren's disease. The CD40L antagonist delivered a statistically significant and clinically meaningful improvement in the primary endpoint, change from baseline in ESSDAI at week 48, strengthening the drug's development outlook.

Analysis

The value inflection for AMGN is less the single indication than validation of CD40L as an autoimmune platform that can support lifecycle expansion across adjacent systemic inflammatory diseases. If safety and durability remain clean, the asset could justify a higher probability-weighted peak-sales contribution than the market assigns to a niche orphan-style launch, particularly because systemic Sjögren's has concentrated specialist prescribers and limited entrenched disease-modifying competition. The key rerating mechanism over the next 6-12 months is not near-term revenue, but a reduction in pipeline-discount applied to Amgen's post-Horizon growth profile.

The important diligence gap is whether the efficacy signal translates into physician-relevant outcomes beyond the composite disease-activity score: steroid reduction, fatigue/dryness improvement, organ-specific responses, discontinuations, and thromboembolic events will determine access and adoption. A strong clinical package could pressure autoimmune peers pursuing broader but less differentiated mechanisms, including UCB's (UCBJF) immunology franchise and FcRn-exposed names such as argenx (ARGX), although cross-indication read-through should be limited until comparative positioning is clearer.

Consensus may overreact to the target-price revision in the near term because commercialization is still distant and biologic reimbursement friction can delay uptake. Conversely, AMGN's large-cap valuation means a modest sales estimate can have outsized multiple impact if it establishes a credible second wave of internally derived growth; the next catalyst is full data disclosure and management's framing of filing timing and addressable population, rather than additional sell-side target changes.

Key Decisions for Investors

• Maintain or initiate a modest AMGN overweight on weakness rather than chase an analyst-note-driven move; target a 6-12 month holding period through full data presentation and regulatory-timing guidance. Thesis requires evidence of clean safety plus meaningful patient-reported and steroid-sparing outcomes; reduce if those details are weak or management narrows the commercial population.
• Use a defined-risk AMGN call spread dated 9-15 months out only after confirming full Phase 3 safety/discontinuation data and an actionable filing timeline. This expresses pipeline multiple expansion while limiting downside if commercialization assumptions are revised; avoid outright short-dated calls because the next material catalyst may not occur for several months.
• Put ARGX and UCBJF on a competitive-risk watchlist, not an immediate short: reassess after the full dataset clarifies whether dazodalibep can compete for systemic autoimmune patients versus FcRn and other targeted therapies. A short thesis would require evidence of superior durability, convenience, or payer economics—not merely statistical significance.
• Monitor AMGN's next earnings call for explicit peak-sales guidance, launch sequencing, and R&D spend implications. A material increase in development spend without a broader indication strategy would cap FCF accretion and weaken the bullish rerating case.